The Exchange has sought clarification from Hikal Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The NSE has asked Hikal Limited to clarify discrepancies found in the XBRL-formatted financial results submitted for the quarter ended September 30, 2025, under Regulation 33 of SEBI's Listing Regulations. The exchange has flagged issues in the XBRL filing and is awaiting the company's response. No details on the nature of the discrepancies have been shared publicly yet. This appears to be a routine compliance query rather than a serious enforcement action.
Minor procedural matter that usually has limited impact on stock price. Shareholders should watch for the company's response, as repeated non-compliance could invite further regulatory scrutiny, but this is unlikely to materially affect business or valuations in the near term.